Patents by Inventor Darko Kantoci

Darko Kantoci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Natriuretic compounds
    Patent number: 6150402
    Abstract: Compounds, methods and compositions are provided for inducing natriuresis in a mammal. Methods for isolating and synthesizing the natriuretic compounds are also provided. Therapeutic methods using the natriuretic compounds are also provided. The natriuretic compounds are capable of inducing sodium excretion in a mammal without inducing corresponding prolongated potassium excretion.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: November 21, 2000
    Assignee: Loma Linda University Medical Center
    Inventors: William J. Wechter, David E. Murray, Darko Kantoci, Barry H. Levine, Elaine J. Benaksas
  • Natriuretic compounds
    Patent number: 6083982
    Abstract: Compounds, methods and compositions are provided for inducing natriuresis in a mammal. Methods for isolating and synthesizing the natriuretic compounds are also provided. Therapeutic methods using the natriuretic compounds are also provided. The natriuretic compounds are capable of inducing sodium excretion in a mammal without inducing corresponding prolonged potassium excretion.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: July 4, 2000
    Assignee: Loma Linda University Medical
    Inventors: William J. Wechter, David E. Murray, Darko Kantoci, Barry H. Levine, Elaine J. Benaksas
  • Natriuretic and anti-hypertensive compounds
    Patent number: 5846967
    Abstract: A compound having the formula I ##STR1## in which R.sub.1, R.sub.2 independently are OH, OOC--R.sub.3 or O--R.sub.3, andR.sub.3 is an unsubstituted or substituted C.sub.1 -C.sub.6 alkyl, alkenyl, alkynyl or phenyl group.The compound is useful as a natriuretic and anti-hypertensive agent.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: December 8, 1998
    Assignee: Loma Linda University Medical Center
    Inventors: William J. Wechter, E. David Murray, Jr., Darko Kantoci
  • Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
    Patent number: 5663149
    Abstract: The synthesis and elucidation of nineteen heterocyclic or halophenyl amide erivatives of dolastatin 10 are disclosed. These compounds and the methods of producing those compounds offer demonstrated significant in vitro activity against several human cancer cell lines. These compounds and the methods of producing those compounds offer a commercially viable alternative to natural and synthetic dolastatin 10.
    Type: Grant
    Filed: December 13, 1994
    Date of Patent: September 2, 1997
    Assignee: Arizona Board of Regents acting on behalf of Arizona State University
    Inventors: George R. Pettit, Jayaram K. Srirangam, Darko Kantoci
  • Human cancer inhibitory pentapeptide amides
    Patent number: 5410024
    Abstract: The synthesis of useful peptides presents a promising approach to new theeutic agents. The Dolastatins, a series of linear and cyclic antineoplastic and/or cytostatic peptides isolated from Indian Ocean sea hare Dolabella auricularia represent excellent leads for synthetic modification.The extraordinary inhibition of cell growth shown by the pentapeptideamides against six major types of human cancer has been presented. The intermediates of these reaction also show anticancer activity against the murine P388 lymphocytic leukemia cell line.
    Type: Grant
    Filed: January 21, 1993
    Date of Patent: April 25, 1995
    Assignee: Arizona Board of Regents acting on behalf of Arizona State University
    Inventors: George R. Pettit, Jozsef Barkoczy, Darko Kantoci
  • New adamantyl comprising tripeptides, derivatives and hydrochlorides thereof, their preparation and use
    Patent number: 5286715
    Abstract: 2-Adamantyl- and 1-adamantyl-D/L-glycyl-L-alanyl-D-isoglutamine and their derivatives of the formulae ##STR1## wherein R stands for a hydrogen atom or a MurNAc group, and hydrochlorides thereof, a process for the preparation thereof and their use to obtain pharmaceuticals, which are particularly indicated for the treatment of viral diseases and tumors and/or immunomodulations in humans and animals.
    Type: Grant
    Filed: November 15, 1991
    Date of Patent: February 15, 1994
    Assignee: Imunoloski Zavod
    Inventors: Branka Vranesic, Jelka Tomasic, Stanislay Smerdel, Darko Kantoci, Gianni Sava, Ivo Hrsak
  • Adamantyl comprising tripeptides, derivatives and hydrochlorides thereof, their preparation and use
    Patent number: 5066642
    Abstract: 2-Adamantyl- and 1-adamantyl-D/L-glycyl-L-alanyl-D-isoglutamine and their derivatives of the formulae ##STR1## wherein R stands for a hydrogen atom or a MurNAc group, and hydrochlorides thereof,a process for the preparation thereof and their use to obtain pharmaceuticals, which are particularly indicated for the treatment of viral diseases and tumors and/or immunomodulations in humans and animals.
    Type: Grant
    Filed: February 9, 1990
    Date of Patent: November 19, 1991
    Assignee: Imunoloski Zavod
    Inventors: Branka Vranesic, Jelka Tomasic, Stanislav Smerdel, Darko Kantoci, Gianni Sava, Ivo Hrsak